clinical trial · NCT05131919
Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers
The Netherlands Cancer Institute·phase2·active not recruiting·n = 25
Colorectal CancerPembrolizumab
brief summary
In this study, the efficacy of pembrolizumab in patients with locally advanced, irresectable dMMR colorectal cancer will be assessed.
started
Dec 22, 2022
primary completion
Jul 1, 2030
completion
Jul 1, 2031
last updated
Dec 9, 2025
detailed description
In this single-center, single arm, open-label, phase II study assessing the efficacy of pembrolizumab in patients with locally advanced, irresectable dMMR colorectal cancer, 25 patients will be enrolled. All patients will be treated with pembrolizumab 200 mg intravenously on day 1 of each 3-week cycle.
official title
Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers. The PUMA Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol